Print

CombiMatrix Corporation (CBMX) Release: National Institutes of Health (NIH) Studies in The New England Journal of Medicine Favor Chromosomal Microarray Analysis Over Standard Karyotyping for Genetic Analysis  
12/7/2012 9:37:08 AM

IRVINE, Calif., Dec. 7, 2012 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that a pair of studies published in a leading journal favor chromosomal microarray analysis (CMA) over traditional karyotyping for genetic prenatal diagnosis and genetic evaluation of stillbirths. The two large studies, published in the current edition of the New England Journal of Medicine, represent the largest head-to-head studies comparing CMA to traditional karyotyping. Both concluded that CMA identified additional, clinically significant genetic abnormalities compared to karyotyping in both the prenatal diagnostic setting as well as the evaluation of stillbirths.
//-->